Navigation Links
Statement from GPhA President and CEO Kathleen Jaeger on FDA's Generic Initiative

ARLINGTON, Va., Oct. 4 /PRNewswire-USNewswire/ -- Generic Pharmaceutical Association (GPhA) President and CEO Kathleen Jaeger today released the following statement regarding the Food and Drug Administration's update on their efforts to improve the generic drug approval process:

"While we all share the goal of increasing efficiency in the generic approval system, another initiative in name only simply will not get the job done. What consumers need is for the FDA to address the core fundamental issues that are blocking timely consumer access to affordable generics. These core issues have been around for more than a decade and include the citizen petition process, scientific consults, enhanced communication, more inspection resources, accountability and structure of the Office of Generic Drug Program.

"For years, the Agency has tinkered around the edges with programs and initiatives designed to increase efficiency but have proven to yield little in the way of significant results. There are serious legislative and regulatory issues that must be addressed to yield a true increase in the number of affordable generics brought to market. The generic industry stands ready to work with the Agency in tackling these issues to increase consumer access. That's why we have entered into good faith efforts with the FDA to create a meaningful user fee program that truly results in timely generic access.

"A significant investment in the generic approval process must ensure that the investment produces a meaningful program with measurable results. A successful user fee program must include robust performance measures; certainty in the review and approval process, including an Agency commitment of resources and recruitment and retention of reviewers; and the closure of barriers to access. If we do not address these long-existing, core fundamental issues, we will simply be throwing money down the drain and be doing little to help consumers get the affordable medicines they need."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 63% of the total prescriptions dispensed in the United States, but only 20% of all dollars spent on prescription drugs.

SOURCE Generic Pharmaceutical Association
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy files registration statement for IPO
2. Mission Statement 2003: Do More with Less and Do it Faster!
3. Siemens health services president calls IT benefits unassailable
4. Wisconsin IT association names Gee president, CEO
5. Merge Healthcare promotes Bowers to president
6. Quintessence Biosciences names new president
7. VanderSanden appointed president of AT&T Wisconsin
8. Merge president steps down in wake of shareholder suits
9. Milwaukees PointOne appoints new president and CEO
10. president slated for Milwaukee event
11. Sonic Foundry names new senior vice president
Post Your Comments:
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
Breaking Biology Technology:
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
Breaking Biology News(10 mins):